Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions

NCT ID: NCT06753318

Last Updated: 2024-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

716 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to learn if a multimodal artificial intelligence (AI) model can enhance the diagnosis of pancreatic solid lesions. The main questions it aims to answer are:

1. Does the AI model enhance the diagnostic performance of endoscopists in diagnosing pancreatic solid lesions?
2. Does the addition of interpretability analysis further improve the diagnostic performance of the assisted endoscopists? Researchers will compare the diagnostic performance of endoscopists with or without the assistance of the AI model.

Participants will:

1. Their clinical data will be prospectively collected.
2. They will be randomized to the AI-assist group and the conventional diagnosis group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators have previously developed a multimodal AI model (Joint-AI) based on endoscopic ultrasound images and clinical data to diagnose pancreatic solid lesions. This study aims to improve the Joint-AI model's performance with a prospectively collected dataset and validate it through a randomized controlled clinical trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer Pancreatitis Pancreatic Neuroendocine Neoplasms (pNETs) Autoimmune Pancreatitis Solid Pseudopapillary Neoplasm of the Pancreas

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pancreatic cancer artificial intelligence endoscopic ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1. First, participants are randomized into three parallel groups: conventional diagnosis group, Joint-AI assistance group, and Interpretable Joint-AI assistance group.
2. For participants within the Joint-AI assistance group and Interpretable Joint-AI assistance group, their groups will be switched after a washout period.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Outcome Assessors
During the endoscopic ultrasound procedure, the allocation of participants will be masked to the endoscopists

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional diagnosis

Endoscopists diagnose pancreatic solid lesions according to endoscopic ultrasound images and clinical data.

Group Type NO_INTERVENTION

No interventions assigned to this group

Joint-AI assisted diagnosis

Endoscopists diagnose pancreatic solid lesions based on endoscopic ultrasound images, clinical data, and predictions made by the Joint-AI model.

Group Type EXPERIMENTAL

The assistance of the Joint-AI model

Intervention Type DIAGNOSTIC_TEST

Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis

Interpretable Joint-AI assisted diagnosis

Endoscopists diagnose pancreatic solid lesions based on endoscopic ultrasound images, clinical data, predictions given by the Joint-AI, and interpretability analysis results used to improve the transparency of the decision-making process of the Joint-AI model.

Group Type EXPERIMENTAL

The assistance of the interpretable Joint-AI model

Intervention Type DIAGNOSTIC_TEST

Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The assistance of the Joint-AI model

Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis

Intervention Type DIAGNOSTIC_TEST

The assistance of the interpretable Joint-AI model

Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Imaging examinations (MRI, CT, B-ultrasound) show a solid mass in the pancreas, which requires endoscopic ultrasound guided-fine needle aspiration/biopsy (EUS-FNA/B) to clarify the nature of the lesion in patients.
* Written consent provided

Exclusion Criteria

* Age under 18 years old
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Union Hosptial

UNKNOWN

Sponsor Role collaborator

Affiliated Drum Tower Hospital of Nanjing University Medical School

UNKNOWN

Sponsor Role collaborator

Shanghai Longhua Hospital

UNKNOWN

Sponsor Role collaborator

Beijing Friendship Hospital

OTHER

Sponsor Role collaborator

Qilu Hospital of Shandong University

OTHER

Sponsor Role collaborator

Sir Run Run Shaw Hospital

OTHER

Sponsor Role collaborator

Huazhong University of Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bin Cheng

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bin Cheng

Role: CONTACT

Phone: 86-13986097542

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bin Cheng

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Joint-AI 2024

Identifier Type: -

Identifier Source: org_study_id